Menu Back toEmerging-Best-Practices-and-Challenges-in-Strategic-Drug-Development-and-Design-Decision-Making

DIA 2018 Global Annual Meeting


Emerging Best Practices and Challenges in Strategic Drug Development and Design Decision Making

    Session Chair(s)
      Cara  Willoughby, MS

      Cara Willoughby, MS

      • Principal Scientific Advisor
      • IQVIA, United States
    This session will present lessons learned and case examples from three different companies who have introduced change initiatives aimed at disrupting and improving strategy and design decision-making. Presentations will share common obstacles, change management pitfalls, critical success factors, and actions you can take now to improve design decision making in your company.
    Learning Objective : Compare and contrast traditional versus emerging strategic drug development and design decision-making practices; Recognize challenges often encountered when implementing new tools, data, processes, and approaches to strategic drug development and design decision-making and describe their impact; Define critical success factors for improving strategic drug development and design decision-making
    Speaker(s)
      Cara  Willoughby, MS

      Perspectives from a Biopharma Service Provider: Design with the End in Mind.

      Cara Willoughby, MS

      • Principal Scientific Advisor
      • IQVIA, United States
      Kyle  Holen, MD

      Leveraging Big Data to Help Design Clinical Program Strategies

      Kyle Holen, MD

      • Head, Development Design Center
      • AbbVie, Inc., United States
      Florian  Bieber, DrMed

      To be determined

      Florian Bieber, DrMed

      • Global Head, Clinical Development and Analytics, Esdtablished Medicines
      • Novartis Pharma AG, United States